Published in Infect Immun on December 01, 1983
Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun (1988) 1.97
The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides. Infect Immun (2004) 1.40
Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci U S A (1985) 1.14
Formation of transmural complement pores in serum-sensitive Escherichia coli. Infect Immun (1987) 1.08
N-linked oligosaccharides of human transferrin are not required for binding to bacterial transferrin receptors. Infect Immun (1990) 1.07
Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect Immun (2001) 1.06
Two-component systems in Haemophilus influenzae: a regulatory role for ArcA in serum resistance. Infect Immun (2003) 1.03
Does complement kill E. coli by producing transmural pores? Immunology (1986) 0.90
Influence of beta-lactam antibiotics and ciprofloxacin on composition and immunogenicity of Escherichia coli outer membrane. Antimicrob Agents Chemother (1986) 0.88
Influence of beta-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli. Antimicrob Agents Chemother (1987) 0.85
Killing of gram-negative bacteria by complement. Fractionation of cell membranes after complement C5b-9 deposition on to the surface of Salmonella minnesota Re595. Biochem J (1989) 0.80
Killing of Gram-negative bacteria with normal human serum and normal bovine serum: use of lysozyme and complement proteins in the death of Salmonella strains O48. Microb Ecol (2009) 0.77
The cytolytic C5b-9 complement complex: feedback inhibition of complement activation. Proc Natl Acad Sci U S A (1988) 0.76
Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition. J Clin Invest (1992) 0.75
C9-mediated killing of bacterial cells by transferred C5b-8 complexes: transferred C5b-9 complexes are nonbactericidal. Infect Immun (1994) 0.75
Mechanism of assembly of the outer membrane of Salmonella typhimurium. Isolation and characterization of cytoplasmic and outer membrane. J Biol Chem (1972) 29.60
Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett (1975) 26.78
The outer membrane proteins of Gram-negative bacteria: biosynthesis, assembly, and functions. Annu Rev Biochem (1978) 7.96
The complement-dependent bacteriolytic activity of normal human serum. I. The effect of pH and ionic strength and the role of lysozyme. J Exp Med (1962) 3.81
Colicins and other bacteriocins with established modes of action. Annu Rev Microbiol (1982) 3.74
LESIONS IN ERYTHROCYTE MEMBRANES CAUSED BY IMMUNE HAEMOLYSIS. Nature (1964) 3.31
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Locus of the lethal event in the serum bactericidal reaction. J Bacteriol (1968) 2.35
The serum bactericidal system: ultrastructural changes in Neisseria meningitidis exposed to normal rat serum. J Exp Med (1969) 2.32
Molecular nature of the complement lesion. Proc Natl Acad Sci U S A (1978) 2.09
Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol (1978) 1.95
Lesions in Escherichia coli membranes after action of antibody and complement. J Bacteriol (1966) 1.94
Effects of colicin K on a mutant of Escherichia coli deficient in Ca 2+, Mg 2+-activated adenosine triphosphatase. J Biol Chem (1974) 1.93
Interaction of E. coli strains with human serum: lack of relationship to K1 antigen. J Pediatr (1976) 1.83
How complement kills E. coli. I. Location of the lethal lesion. J Immunol (1981) 1.74
[Studies on the immune bacteriolysis. XIV. Requirement of all nine components of complement for immune bacteriolysis]. Biken J (1968) 1.70
Viability of Escherichia coli treated with colicin K. Proc Natl Acad Sci U S A (1975) 1.55
Molecular organization of the outer membrane of Salmonella typhimurium. Eur J Biochem (1979) 1.41
Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme. Infect Immun (1980) 1.40
Characterization of a low density cytoplasmic membrane subfraction isolated from Escherichia coli. Biochim Biophys Acta (1975) 1.40
Killing of an encapsulated strain of Escherichia coli by human serum. Infect Immun (1983) 1.35
The regulation of potassium fluxes for the adjustment and maintenance of potassium levels in Escherichia coli. Eur J Biochem (1981) 1.30
Release of phospholipids from complement-mediated lesions on the surface structure of Escherichia coli. J Immunol (1977) 1.27
Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death. J Exp Med (1982) 1.25
Effects of human and rabbit serum on viability, permeability, and envelope lipids of Serratia marcescens. Infect Immun (1975) 1.23
Chemical studies on damages of Escherichia coli by the immune bactericidal reaction. I. Release and degradation of phospholipids from damaged bacteria. Biken J (1974) 1.21
Immunochemical investigations on lipopolysaccharides and acidic polysaccharides from serum-sensitive and serum-resistant strains of Escherichia coli isolated from urinary-tract infections. J Med Microbiol (1976) 1.13
Evidence for a two-domain structure of the terminal membrane C5b-9 complex of human complement. Proc Natl Acad Sci U S A (1979) 1.11
Immunochemical analyses of membrane-bound complement. Detection of the terminal complement complex and its similarity to "intrinsic" erythrocyte membrane proteins. Biochim Biophys Acta (1975) 1.10
Analysis of solute diffusion across the C5b-9 membrane lesion of complement: evidence that individual C5b-9 complexes do not function as discrete, uniform pores. J Immunol (1980) 1.09
Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event? J Immunol (1976) 0.94
Permeability characteristics of complement-damaged membranes: evaluation of the membrane leak generated by the complement proteins C5b-9. Proc Natl Acad Sci U S A (1981) 0.90
Membrane damage by complement. Johns Hopkins Med J (1981) 0.87
Studies on the immune bacteriolysis. 13. Leakage of enzymes from Escherichia coli during immune bacteriolysis. Biken J (1968) 0.87
Molecular transport via the functional complement lesion. Mol Immunol (1980) 0.82
Lipase activity of detergent-resistant phospholipase A in Escherichia coli. Biochim Biophys Acta (1974) 0.80
Role of bacterial phospholipases in serum-mediated killing of Escherichia coli. Infect Immun (1977) 0.79
Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev (1983) 5.73
On the mechanism of membrane damage by Staphylococcus aureus alpha-toxin. J Cell Biol (1981) 4.06
Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. Infect Immun (1986) 3.94
Mechanism of membrane damage by streptolysin-O. Infect Immun (1985) 3.26
Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. J Clin Microbiol (1995) 3.04
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev (1999) 2.76
Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A (2001) 2.67
Production of listeriolysin by beta-hemolytic strains of Listeria monocytogenes. Infect Immun (1986) 2.66
Isolation and identification of two hemolytic forms of streptolysin-O. Infect Immun (1984) 2.57
Novel path to apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T lymphocytes evoke internucleosomal DNA degradation. Infect Immun (1994) 2.47
Staphylococcal alpha-toxin: oligomerization of hydrophilic monomers to form amphiphilic hexamers induced through contact with deoxycholate detergent micelles. Proc Natl Acad Sci U S A (1981) 2.38
A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med (1996) 2.37
Damage to mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol (1987) 2.36
Damage to cell membranes by pore-forming bacterial cytolysins. Prog Allergy (1988) 2.23
Evaluation of a technique for the estimation of serum bactericidal activity against Gram-negative organisms. Med Lab Technol (1972) 2.19
Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol (1998) 2.16
Molecular nature of the complement lesion. Proc Natl Acad Sci U S A (1978) 2.09
Staphylococcal alpha-toxin kills human keratinocytes by permeabilizing the plasma membrane for monovalent ions. Infect Immun (1993) 2.09
Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J (1995) 2.08
Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation (2001) 2.02
Correlation between toxin binding and hemolytic activity in membrane damage by staphylococcal alpha-toxin. Infect Immun (1984) 2.01
Membrane damage by complement. Biochim Biophys Acta (1983) 2.00
Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes. Scand J Immunol (1978) 1.95
Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol (1995) 1.94
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83
Isolation and characterization of a pigmentless-conidium mutant of Aspergillus fumigatus with altered conidial surface and reduced virulence. Infect Immun (1997) 1.82
Subcytocidal attack by staphylococcal alpha-toxin activates NF-kappaB and induces interleukin-8 production. Infect Immun (2001) 1.71
Protein sorting in Plasmodium falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. Biochem J (1996) 1.64
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Escherichia coli haemolysin forms voltage-dependent ion channels in lipid membranes. Biochim Biophys Acta (1987) 1.61
Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc Natl Acad Sci U S A (1997) 1.58
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Mechanism of complement cytolysis and the concept of channel-forming proteins. Philos Trans R Soc Lond B Biol Sci (1984) 1.57
Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res (1996) 1.55
Murein biosynthesis and O-acetylation of N-acetylmuramic acid during the cell-division cycle of Proteus mirabilis. Eur J Biochem (1981) 1.54
Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta (1976) 1.47
Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest (1999) 1.47
Helicobacter sp. strain Mainz isolated from an AIDS patient with septic arthritis: case report and nonradioactive analysis of 16S rRNA sequence. J Clin Microbiol (1994) 1.45
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Inflammation of the deep infrapatellar bursa of the knee. Arthritis Rheum (1989) 1.42
Serum bactericidal activity in patients with upper and lower urinary tract infections. Clin Sci (1972) 1.42
Enthesitis of the elbow in psoriatic arthritis. J Rheumatol (1997) 1.42
Minimal requirements for exocytosis. A study using PC 12 cells permeabilized with staphylococcal alpha-toxin. J Biol Chem (1985) 1.40
Detection of amphiphilic proteins and peptides in complex mixtures. Charge-shift crossed immunoelectrophoresis and two-dimensional charge-shift electrophoresis. Biochim Biophys Acta (1977) 1.38
Neuraminidase associated with coliphage E that specifically depolymerizes the Escherichia coli K1 capsular polysaccharide. J Virol (1985) 1.38
Genetical studies of serum resistance in Escherichia coli. J Gen Microbiol (1975) 1.37
The terminal membrane C5b-9 complex of human complement. Evidence for the existence of multiple protease-resistant polypeptides that form the trans-membrane complement channel. J Immunol (1980) 1.36
Killing of an encapsulated strain of Escherichia coli by human serum. Infect Immun (1983) 1.35
Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest (1990) 1.35
Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int (1986) 1.33
Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA (1999) 1.32
Identification with monoclonal antibodies of hemolysin produced by clinical isolates of Escherichia coli. J Clin Microbiol (1987) 1.32
Staphylococcus aureus alpha-toxin. Dual mechanism of binding to target cells. J Biol Chem (1991) 1.30
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Plasmid carriage and the serum sensitivity of enterobacteria. Infect Immun (1978) 1.30
A protein factor associated with serum resistance in Escherichia coli. J Med Microbiol (1977) 1.29
Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. J Clin Microbiol (1996) 1.29
Use of a monoclonal antibody to determine the mode of transmembrane pore formation by streptolysin O. Infect Immun (1986) 1.28
Determinants that increase the serum resistance of Escherichia coli. Infect Immun (1980) 1.28
Quantitative study of the binding and hemolytic efficiency of Escherichia coli hemolysin. Infect Immun (1989) 1.27
Recovery of human fibroblasts from attack by the pore-forming alpha-toxin of Staphylococcus aureus. Microb Pathog (1994) 1.27
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblotting as a serological tool in the diagnosis of syphilitic infections. J Clin Microbiol (1985) 1.27
Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J Biol Chem (1983) 1.26
Potassium regulates IL-1 beta processing via calcium-independent phospholipase A2. J Immunol (2000) 1.25
Cytocidal effects of Escherichia coli hemolysin on human T lymphocytes. Infect Immun (1993) 1.25
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Characterization of a catalase-negative methicillin-resistant Staphylococcus aureus strain. J Clin Microbiol (2007) 1.25
The capsular polysaccharide is a major determinant of serum resistance in K-1-positive blood culture isolates of Escherichia coli. Infect Immun (1990) 1.24
Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol (1998) 1.23
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother (1994) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus. Infect Immun (1996) 1.22
Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Biosci Rep (1985) 1.21
Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest (1989) 1.21
Molecular architecture of a toxin pore: a 15-residue sequence lines the transmembrane channel of staphylococcal alpha-toxin. EMBO J (1996) 1.21
Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol (1990) 1.20
Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol (1998) 1.20
Staphylococcal alpha-toxin: formation of the heptameric pore is partially cooperative and proceeds through multiple intermediate stages. Biochemistry (1997) 1.19
Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods (1987) 1.19
Staphylococcus aureus alpha-toxin. Production of functionally intact, site-specifically modifiable protein by introduction of cysteine at positions 69, 130, and 186. J Biol Chem (1993) 1.19
Sensitivity of some smooth strains of Escherichia coli to the bactericidal action of normal human serum. J Clin Pathol (1974) 1.18
Surgical procedure affects physiological parameters in rat myocardial ischemia: need for mechanical ventilation. Am J Physiol (1999) 1.17
C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. J Immunol (1986) 1.16
Oligomerization of Vibrio cholerae cytolysin yields a pentameric pore and has a dual specificity for cholesterol and sphingolipids in the target membrane. J Biol Chem (1999) 1.16
Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5b-9 complex of human complement. J Immunol (1978) 1.16
Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. J Immunol (1981) 1.16
Effects of Escherichia coli hemolysin on endothelial cell function. Infect Immun (1990) 1.16
Terminal membrane C5b-9 complex of human complement: transition from an amphiphilic to a hydrophilic state through binding of the S protein from serum. J Cell Biol (1982) 1.16
Potent membrane-permeabilizing and cytocidal action of Vibrio cholerae cytolysin on human intestinal cells. Infect Immun (1997) 1.15
Molecular weight of the membrane C5b-9 complex of human complement: characterization of the terminal complex as a C5b-9 monomer. Proc Natl Acad Sci U S A (1981) 1.15
Identification of a unique Helicobacter species by 16S rRNA gene analysis in an abdominal abscess from a patient with X-linked hypogammaglobulinemia. J Clin Microbiol (2000) 1.15
Generation of leukotrienes and lipoxygenase factors from human polymorphonuclear granulocytes during bacterial phagocytosis and interaction with bacterial exotoxins. Zentralbl Bakteriol Mikrobiol Hyg A (1983) 1.14
Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J Clin Invest (1991) 1.13
Complete nucleotide sequence of the gene encoding bacteriophage E endosialidase: implications for K1E endosialidase structure and function. Biochem J (1995) 1.13
Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol (1986) 1.13
Immunochemical investigations on lipopolysaccharides and acidic polysaccharides from serum-sensitive and serum-resistant strains of Escherichia coli isolated from urinary-tract infections. J Med Microbiol (1976) 1.13
Isolation and separation of physicochemically distinct fimbrial types expressed on a single culture of Escherichia coli O7:K1:H6. Infect Immun (1985) 1.12